Robichaud A, Fereydoonzad L, Schuessler TF. Delivered dose estimate to standardize airway hyperresponsiveness assessment in mice. Am J Physiol Lung Cell Mol Physiol 308: L837-L846, 2015. First published January 30, 2015 doi:10.1152/ajplung.00343.2014.-Airway hyperresponsiveness often constitutes a primary outcome in respiratory studies in mice. The procedure commonly employs aerosolized challenges, and results are typically reported in terms of bronchoconstrictor concentrations loaded into the nebulizer. Yet, because protocols frequently differ across studies, especially in terms of aerosol generation and delivery, direct study comparisons are difficult. We hypothesized that protocol variations could lead to differences in aerosol delivery efficiency and, consequently, in the dose delivered to the subject, as well as in the response. Thirteen nebulization patterns containing common protocol variations (nebulization time, duty cycle, particle size spectrum, air humidity, and/or ventilation profile) and using increasing concentrations of methacholine and broadband forced oscillations (flexiVent, SCIREQ, Montreal, Qc, Canada) were created, characterized, and studied in anesthetized naïve A/J mice. A delivered dose estimate calculated from nebulizer-, ventilator-, and subject-specific characteristics was introduced and used to account for protocol variations. Results showed that nebulization protocol variations significantly affected the fraction of aerosol reaching the subject site and the delivered dose, as well as methacholine reactivity and sensitivity in mice. From the protocol variants studied, addition of a slow deep ventilation profile during nebulization was identified as a key factor for optimization of the technique. The study also highlighted sensitivity differences within the lung, as well as the possibility that airway responses could be selectively enhanced by adequate control of nebulizer and ventilator settings. Reporting results in terms of delivered doses represents an important standardizing element for assessment of airway hyperresponsiveness in mice. airway hyperresponsiveness; delivered dose; methacholine; forced oscillation technique; nebulizer
AIRWAY HYPERRESPONSIVENESS (AHR) is an important defining feature of asthma and its severity. In humans, it is commonly assessed through a bronchoprovocation test, in which the patient's airways are challenged with increasing concentrations of an inhaled bronchoconstrictor agent. Key features of the response curve help establish whether AHR is present. Typically, a patient with AHR responds at a lower bronchoconstrictor concentration, reacts more, and reaches a greater maximal response than a normal subject (4, 26) . Therefore, leftward and upward shifts, as well as steeper slopes, can be observed in the dose-response curves of these patients compared with normal subjects (4, 26) .
In a similar manner, aerosolized methacholine is commonly used to assess AHR in mice, and exaggerated responses can be observed, for example, in allergically inflamed mice compared with sham-treated animals (16, 17, 25, 29, 30, 34, 37) . Since this often constitutes a primary study outcome, the procedure is performed in a large number of laboratories. However, no standardized procedure exists; therefore, protocol variations can frequently be found in the literature, even when the same measurement technique is used. Close scrutiny of a list of research articles where the forced oscillation technique, an invasive measurement approach referred by some as the "gold standard" for respiratory mechanics assessment (22) , was used to evaluate AHR to aerosolized methacholine in mice commonly reveals variations affecting the aerosol generation or delivery aspect of the protocol (1, 3, 16, 17, 25, 29, 30, (33) (34) (35) 37) . For example, in the latter selection of articles, at least four different nebulizers were used, nebulization time varied from 4 to 90 s, and changes in the ventilation profile or modifications to the inspiratory line were sometimes introduced. Some studies also contained partial descriptions of the nebulization aspect of the protocol that would be insufficient to accurately reproduce the experiments.
Although individually these studies report accurate measurements of respiratory mechanics, difficulties arise when they are considered collectively or when results are compared between specific studies. Parameters affecting aerosol generation or delivery, such as the choice of nebulizer, the nebulization time, the ventilation profile during nebulization, or the control of humidity, could conceivably influence the amount, properties, delivery, distribution, or deposition of the aerosol generated (18, 19, 24, 27) . Nevertheless, results are typically reported in terms of increasing concentrations of methacholine initially used to generate the aerosol, thus neglecting the details of how it was produced and transported. Moreover, studies that have assessed the impact of aerosol-related protocol variations on respiratory mechanics or AHR profiles in mice are scarce (2) .
In the present study we hypothesized that the nebulizer and ventilator settings employed during nebulization could influence the aerosol delivery efficiency and, consequently, the dose of aerosolized bronchoconstrictor delivered to the subject's airways, as well as the functional respiratory mechanics end points measured. To demonstrate this, we created, characterized, and evaluated in mice a series of 13 nebulization patterns composed using variations in a total of 5 different experimental parameters, namely, nebulization time, nebulizer duty cycle, particle size spectrum, air humidity, and ventilation profile during nebulization. To assess the impact of nebulization protocol variations on the dose, we introduced an estimate of the dose of aerosolized bronchoconstrictor agent delivered at the subject's airways and used it to evaluate the impact of protocol variations on the reactivity and sensitivity of the mouse to respiratory system aerosolized methacholine.
MATERIALS AND METHODS
Subjects. Naïve, adult, male A/J mice (6 -8 wk old, 24.1 Ϯ 0.3 g body wt at the time of the study) were purchased from The Jackson Laboratory (Bar Harbor, ME) and housed according to the guidelines of the Canadian Council on Animal Care at the animal facility of the research center of the Centre Hospitalier de l'Université de Montréal (Montreal, Qc, Canada), where the experiments were conducted. All animal procedures were approved before the study by the Centre Hospitalier de l'Université de Montréal Institutional Animal Protection Committee.
Experimental setup. Nebulization patterns were characterized and changes in respiratory mechanics were studied using a legacy flexiVent system or a flexiVent FX operated by flexiVent v5.3 or flexiWare v7.5, respectively (SCIREQ, Montreal, Qc, Canada). The system included an Aeroneb Lab nebulizer (Aerogen, Galway, Ireland) integrated into the inspiratory branch of the Y tubing. Two nebulizer models, differing in the particle size spectrum produced, were used: one standard-and one small-particle-sized model (4 -6 and 2.5-4 m, respectively, according to the manufacturer's specifications). Nebulizer activation was computer-controlled and synchronized with the inspiratory part of ventilation. Once activated, each nebulizer was pulsed with a cycle time of 40 ms for the entire duration of the nebulization period. The percentage of time during which the device was active during each cycle was controlled by the duty cycle setting, where 100% would represent maximal intensity.
Nebulizer characterization. The volume of aerosol produced by any given nebulizer is relative to its absolute aerosol output rate, which can vary between units or nebulizer type but can be determined gravimetrically. To determine the absolute aerosol output per unit of time of the two nebulizer models, we attached each nebulizer to a previously calibrated precision load cell (model S100, Strain Measurement Devices) and, using a separate data acquisition system (DAC-08 controller and flexiWare software, SCIREQ), recorded weight changes during nebulization. While attached to the precision load cell, the nebulizer was connected to the flexiVent system and controlled by the operating software but was not mounted in the inspiratory line of the system. Once activated, aerosol was released from underneath the nebulizer into the open, and weight changes were collected at a sampling rate of 100 Hz. A low-pass filter was applied using a sixth-order Bessel filter with a cutoff frequency of 5 Hz to suppress noise caused by slight vibrations of the test setup. Each nebulizer was activated for five consecutive 60-s test runs at four relative duty cycle settings between 25 and 100% using a continuous mode of operation. Absolute aerosol output rates (in ml/min) were calculated for each run from the recorded weight differences and the known density of the liquid. Then all five runs were averaged for each of the four relative duty cycle settings tested. We performed a similar experiment in which nebulizers were synchronized with inspiration. We also conducted additional measurements to test whether the aerosol output depended on the level of liquid in the reservoir and found that this was not the case.
Nebulization patterns and characterization. Departing from a default nebulization protocol integrated in the system operating software (pattern 1, Table 1 ), we created 12 variations by deviating from the initial protocol in at least 1 of the following 5 parameters: 1) nebulization time (2.5-20 s), 2) nebulizer duty cycle (25-100%), 3) nebulizer particle size spectrum (4 -6 or 2.5-4 m), 4) inspired air humidity (presence or absence of a Drierite-containing desiccant cartridge attached to the air intake), and 5) ventilation profile during nebulization [regular (150 breaths/min, 10 ml/kg) or slow deep (50 breaths/min, 30 ml/kg) ventilation]. The fraction of nebulized aerosol reaching the subject site was characterized gravimetrically for each nebulization pattern on the basis of previously described methodology (24) . Briefly, the nebulizer and a Drierite-containing desiccant cartridge, which was used as a subject filter to capture humidity, were weighed before and after nebulization on a four-decimal precision balance. Each determination consisted of running a given nebulization pattern four to eight times with ϳ1 min of default ventilation between runs. The increase in the subject filter weight was then expressed relative to the decrease in the nebulizer weight. A total of three to nine determinations were performed for each pattern, with care taken to start each determination with dry components.
Since a completely redesigned version of the flexiVent system (flexiVent FX) was introduced following the initiation of this study (28) , we also conducted tests to verify that the fraction of nebulized aerosol reaching the subject site was consistent between the system versions under default settings. More specifically, patterns 1 and 7 were gravimetrically characterized for the fraction of nebulized aerosol reaching the subject site on a flexiVent FX system operated by flexiWare v7.5, the latest version of the software at the time of the study.
AHR assessment in mice. Experiments were conducted in a procedure room where temperature and ambient air humidity were maintained at 21°C and 45%, respectively. For each experimental condition, mice were sedated with an injection of xylazine hydrochloride (8 mg/kg ip) and anesthetized 5 min later by administration of pentobarbital sodium (70 mg/kg ip). If required, an anesthetic supplement (0.25-0.50 dose) was administered intraperitoneally. Once the desired level of anesthesia was reached, as assessed by loss of withdrawal reflex and absence of response to an external stimulus, each mouse was tracheotomized, cannulated, and connected to the flexiVent system for mechanical ventilation and lung function measurements using the forced oscillation technique (25) . An 18-gauge metal cannula with a typical resistance of 0.2 cmH 2O·s·ml Ϫ1 was used for tracheal cannulation in an attempt to minimize airflow resistance at that level. Throughout the experiments, mice were either placed on a heating pad equipped with a rectal temperature probe to maintain body temperature or wrapped temporarily in thermally insulating material to minimize heat loss (10) . Body temperature measurements were not recorded. All animals were mechanically ventilated using a typical ventilation pattern, i.e., respiratory rate of 150 breaths/min, tidal volume of 10 ml/kg, inspiratory-to-expiratory ratio of 2:3, and positive endexpiratory pressure of 3 cmH 2O. After the animal was connected to the flexiVent, lung volume history was standardized by administration of two deep lung inflations, i.e., slow inflations to 30 cmH2O over 3 s held for an additional 3 s. After establishment of a stable baseline and 2 min of mechanical ventilation, baseline respiratory mechanics measurements were collected before administration of a saline challenge followed by up to six aerosolized methacholine (acetyl-␤-methylcholine chloride; Sigma-Aldrich) challenges of increasing concentrations, with methacholine solutions being prepared in pH-buffered saline (14) as free drug. Methacholine-induced bronchoconstriction was recorded over a period of 3 min postchallenge using a broadband low-frequency forced-oscillation (LFOT) maneuver that contained 13 mutually prime frequencies between 1 and 20.5 Hz (Quick Prime-3). Automated LFOT measurements were executed every 15 s, starting immediately after aerosol generation, for a total of 12 automated closely spaced measurements for each challenge. Between consecutive challenges, the animal's lungs were subjected to two deep lung inflations, as described above; then LFOT was measured to assess respiratory system mechanics. Under these experimental conditions, the duration of a typical AHR assessment session was ϳ30 min.
The constant-phase model (13) was fit to the respiratory input impedance calculated from the LFOT data directly in the operating software, yielding parameters such as Newtonian resistance (R N), tissue damping (G), and tissue elastance (H), which allow partitioning of the response into airway (R N) and lung tissue (G and H) mechanics. Parameters from individual data sets were included in the subsequent analysis, provided that the coefficient of determination assessing the fit of the model to the experimental data was Ն0.9. Throughout the study, the average number of accepted data sets following an aerosol challenge was 11.3 Ϯ 0.1, and there was no statistical difference between the different experimental conditions. Delivered dose calculation. For each animal, the amount of methacholine delivered to the animal's airways (m del) was calculated after every challenge according to the following equations
where Cair,ao is the concentration of methacholine in the inspiratory airflow passing through the animal's airway opening (in mg/ml, taking into account transport delays between nebulizer and airway opening and assuming bulk flow), V ao,insp is the inspiratory airflow through the cannula or intubation tube (in ml/s), t is the duration of the nebulization period (in s), fdel is the fraction of nebulized aerosol reaching the subject site, Cair,N is the concentration of methacholine in the inspiratory airflow passing the nebulizer (in mg/ml), Cliq is the concentration of methacholine in the solution loaded into the nebulizer (in mg/ml), Q N is the nebulization rate of the nebulizer (in ml/s), and V N is the airflow passing the nebulizer (in ml/s). Equations 1 and 2 were adapted from previously reported inhaled drug exposure dose calculations in conscious mice (11) . Data analysis. The reactivity (or steepness of change) and sensitivity (or measure of the position of the curve along the x-axis) aspects of individual dose-response curves were analyzed by calculating, respectively, the slope and the provocative dose of methacholine required to induce a twofold increase over baseline (PD 200) for each subject and parameter. The slope of the dose-response curve was calculated by linear regression analysis of the natural logarithm of the peak response against the calculated dose of aerosolized methacholine delivered to the animal's airways (31, 36) . Methacholine PD 200 was calculated by fitting a second-order polynomial to the dose-response data and interpolating the resulting curve. PD200 values were normalized to the animal's weight and expressed in micrograms of methacholine per gram of body weight. Compared with a control condition, an increased slope would indicate an increased reactivity, while a decrease in PD 200 would point to a leftward shift in the dose-response curve and, therefore, an increased sensitivity.
The distinction in methacholine reactivity or sensitivity between airways and lung tissue was evaluated from a functional point of view through the LFOT and use of the constant-phase model, which provides a means of partitioning the response (13, 25) . Reactivity (slope of the dose-response curve) or sensitivity (PD 200 value) parameters associated with each of the constant-phase model parameters, RN, G, and H, were grouped and compared.
Nebulization patterns were compared with pattern 1 to identify protocol variations associated with overall outcome improvements relative to the default pattern (i.e., pattern 1). We used a unified parameter that we derived from key dose-response features associated with AHR using the following equation and referred to as responsiveness index (RI)
where S DRC is the average slope of the dose-response curve for a given nebulization pattern, PD200 is the pattern average provocative dose required to cause a doubling of baseline value, Peak is the pattern mean maximal value obtained at an analogous delivered dose across patterns, which, in the present study, was 11 (range 9 -13) g to include as many patterns as possible in the analysis, m del is the pattern average delivered dose at which peak response was extracted, and CV b-s is the average between-subject coefficient of variation (i.e., mean/standard deviation) at the selected analogous dose used for peak determination. CVb-s was calculated over the entire collection of automated measurements taken at that specific challenge by averaging the individual CVb-s associated with each measurement. RI was calculated for each of the constant-phase model parameters (e.g., RN, G, and H) and each pattern included in the comparison. For comparison purposes, RI, which described each pattern through a single number, was expressed as a percentage of pattern 1, and a value Ͼ100% was interpreted as an improvement relative to the default nebulization pattern (pattern 1). Statistical analysis. Differences between groups were determined by t-test or ANOVA followed by Dunnett's t-test for mean comparison with pattern 1 (GraphPad Prism version 5, GraphPad Software, San Diego, CA). Differences at P Ͻ 0.05 were considered statistically significant. Values are means Ϯ SE; n is the number of animals or determinations per group.
RESULTS
Nebulizer and nebulization pattern characterization. The aerosol output rate of each nebulizer is presented in Fig. 1 under two operating modes: continuous and synchronized with inspiration. As expected, aerosol output rates increased linearly over the duty cycle range studied under both operating conditions and for each model of nebulizer (Fig. 1) . In agreement with the manufacturer's specifications, the slopes of the nebulizers' output rates over increasing duty cycle were different between nebulizer types. At maximal intensity (i.e., 100% duty cycle) under both operating modes, the nebulizer that produced standard-sized particles generated a significantly larger volume of aerosol per unit of time than the nebulizer that produced smaller particles. It was possible to operate each nebulizer at equivalent aerosol output rates under both operating modes. For example, no statistically significant difference was found between the aerosol output rates recorded with the nebulizer that produced standardsized particles at 25% duty cycle and the nebulizer that produced smaller particles at 50% duty cycle (Fig. 1) . After a typical nebulization pattern (pattern 1, Table 1 ), the average volume of aerosol generated was determined to be 18.3 Ϯ 1.0 l for the nebulizer that produced standard-sized particles and 10.5 Ϯ 0.4 l for the nebulizer that produced smaller particles.
The gravimetrically determined fraction of nebulized aerosol that reached the subject site varied according to the nebulization protocol (Table 2) . More specifically, an ultrashort nebulization time (patterns 2 and 11), a reduced duty cycle (pattern 5), a combination of both (patterns 12 and 13), or the use of a nebulizer that produces small particles (pattern 7) was associated with an improved aerosol delivery efficiency relative to pattern 1. In contrast, increasing the duty cycle of the nebulizer to its maximal capacity (pattern 6) resulted in the opposite effect. That setting was inversely proportional to the percentage of nebulized aerosol gravimetrically recovered at the subject site (r 2 ϭ 0.9112). The other protocol variations had no significant effect on the fraction of nebulized aerosol at the subject site relative to the default pattern (pattern 1, Table 2 ). Also, there was no statistically significant difference in the fraction of aerosol reaching the subject site between versions of the flexiVent system (legacy flexiVent vs. flexiVent FX) under default settings for both nebulizer types. The average fraction of aerosol at the subject site obtained with the flexiVent FX was determined to be 0.109 Ϯ 0.020 (n ϭ 9) for the nebulizer that produced standard-sized particles (pattern 1) and 0.202 Ϯ 0.037 (n ϭ 9) for the nebulizer that produced smaller particles (pattern 7).
Delivered dose. For all nebulization patterns, the delivered doses estimated using Eqs. 1 and 2 increased linearly over the range of methacholine concentrations (Fig. 2) . Statistically significant differences in slopes between patterns were noted. Pattern 4 generated significantly higher doses of methacholine than pattern 1; in contrast, patterns 2, 3, 6, and 10 -13 delivered significantly lower doses than pattern 1 (Fig. 2) . The remaining four patterns (patterns 5 and 7-9) produced doses similar to the default pattern (pattern 1). As expected, the doses generated by nebulization of typical concentrations of metha- Table 1 ). Delivered doses were calculated using nebulizer-, ventilator-, and subject-specific parameters acquired during prior calibration maneuvers, as well as during the time of nebulization (see Eqs. 1 and 2). Values were corrected for condition, i.e., fraction of aerosol reaching the subject site (see Table 2 ). Values are means Ϯ SE; n ϭ 3-8 animals per group. *P Ͻ 0.05 vs. pattern 1 slope comparison (by ANOVA).
choline varied between nebulization patterns. As shown in Fig.  2 , the delivered doses produced by 3.125 mg/ml methacholine quadrupled from 2.55 Ϯ 0.01 g (pattern 13) to 10.91 Ϯ 0.20 g (pattern 4), while the delivered doses generated by 12.5 mg/ml methacholine varied between 9.35 Ϯ 0.03 g (pattern 11) and 40.72 Ϯ 2.28 g (pattern 4) and those generated by 50 mg/ml methacholine varied between 37.0 Ϯ 0.29 g (pattern 11) and 91.59 Ϯ 2.72 g (pattern 9). Changes in reactivity to aerosolized methacholine. Relative to condition-specific control groups, reactivity to aerosolized methacholine in A/J mice significantly increased when nebulization time was doubled (Fig. 3A, pattern 4) , the particle size spectrum of the nebulizer was reduced (Fig. 3C, pattern 7) , the ventilation program was switched to a slow deep mode during nebulization [ Fig. 3E, pattern 10 ; and pattern 11 (not shown)], or a combination of reduced nebulizer and ventilator setting was employed (Fig. 3F, pattern 13) . Reactivity significantly decreased when nebulization time was reduced, as observed by a statistically significant difference in slope for each respiratory mechanics parameter (Fig. 3A, pattern 2) . Variations in nebulizer duty cycle or air intake humidity did not significantly affect reactivity to aerosolized methacholine.
Changes in sensitivity to aerosolized methacholine. As shown in Fig. 4A , sensitivity to aerosolized methacholine was negatively influenced by an ultrashort nebulization time (pattern 2), as reflected by a significant increase in PD 200 . Sensitivity to aerosolized methacholine was improved (i.e., a decrease in PD 200 ) by addition of a slow deep ventilation profile during nebulization, alone (Fig. 4B, pattern 10 ) or in combination with other protocol modifications (Fig. 4C, pattern 13) . PD 200 was not affected by the other variations (i.e., duty cycle, particle size spectrum, or intake air humidity level).
Partitioning of the response. Reactivity to aerosolized methacholine did not differ between airway (R N ) and lung tissue (G Fig. 3 . Effect on reactivity. Slope of individual dose-response curve (SDRC) was calculated for every nebulization pattern and grouped according to the different experimental conditions (see Table 1 ). RN, Newtonian resistance, which reflects resistance of the airways; G, tissue damping, which reflects tissue viscoelasticity and is closely related to tissue resistance; H, tissue elastance. Values are means Ϯ SE; n ϭ 3-8 animals per group. *P Ͻ 0.05 vs. pattern 1 or relevant control group (by t-test or ANOVA for each constant-phase model parameter). and H), as shown by similar slopes between the three constantphase model parameters (Fig. 5) . On the other hand, sensitivity to aerosolized methacholine was statistically influenced by the regional distinction provided by application of the constant-phase model to input impedance, as reflected by an increase in PD 200 for H (i.e., decrease in H sensitivity) relative to R N and G (Fig. 5) .
Pattern comparison. Comparison of the 12 nebulization pattern variations with pattern 1 on the basis of a calculated RI derived from key dose-response features associated with AHR identified the addition of a slow deep ventilation profile during nebulization (Fig. 6, pattern 10) as the protocol modification producing by far the largest overall enhancing effect on measured AHR end points. That modification led to increases in RI values for all three constant-phase model parameters (R N , G, and H) relative to pattern 1. As shown in Fig. 6 , RI enhancements of considerably less magnitude were also seen for all three constant-phase model parameters with four other nebulization patterns (patterns 4, 6, 7, and 11). Pattern 13 distinguished itself, in that it was associated with an improved RI for R N relative to pattern 1, as well as worsening effects for the constant-phase model parameters related to lung tissue mechanics (G and H). The other protocol modifications (patterns 2, 3, 5, and 12) resulted in either no effects or worsening effects on RI relative to pattern 1. Figure 7 illustrates changes in R N and H from three nebulization protocol variations identified through the pattern comparison described above (patterns 1, 10, and 13). In Fig. 7 , A and C, changes in R N and H relative to baseline are plotted in terms of increasing methacholine concentrations loaded into the nebulizer; in Fig. 7 , B and D, the same curves are represented as a function of the average dose delivered at the subjects' airways. When protocol variations were taken into account, results showed that the changes in R N under the three nebulization protocols could be ranked along the dose axis, with patterns 10 and 13 shifted to the left relative to pattern 1 (Fig. 7B) . Similar results were also observed with changes in H, with the following two exceptions: 1) pattern 13 appeared slightly at the right of pattern 1, and 2) the difference in the magnitude of change between the two nebulization patterns at the highest methacholine concentration (Fig. 7C) became attenuated when the details of the nebulization protocols were taken into account and the responses compared at similar doses (Fig. 7D) .
Delivered dose effect.

DISCUSSION
Exposure of mice to increasing challenges of aerosolized methacholine for AHR assessment constitutes a key aspect of A B C Fig. 4 . Effect on sensitivity. Provocative methacholine dose required to induce a 2-fold increase over baseline (MCh PD200) was calculated for individual parameters and animals by fitting a 2nd-order polynomial to the dose-response data and interpolating the resulting curve. Values are means Ϯ SE; n ϭ 3-8 animals per group. In C, average PD200 value is missing for parameter H in pattern 12 because of an insufficient number of subjects reaching a doubling of baseline within the dose range studied. Details of each nebulization pattern are listed in Table 1 Table 1 for details of each nebulization patterns.
a large number of preclinical respiratory studies, since the end points are frequently considered of primary importance. During result analysis, peak responses are typically expressed relative to the concentrations of the bronchoconstrictor solutions loaded into the nebulizer. Although this approach is widely accepted, it has an important weakness, in that results are comparable only if identical protocols are used. While steps were recently made to standardize this widely used technique, as well as to increase the translational utility of AHR measurements in mice (22, 36) , variations in the aerosol generation or transport aspect of the protocol are common. The rationale for such variations is not disputed, as they may be required to address specific scientific questions. However, the facts that they exist, that they are frequent, and that they risk influencing the amount or properties of the aerosol generated (18, 19, 24, 27) highlight the need for a way to account for them to adequately reflect and interpret results, as well as to facilitate study comparisons.
In the present study, five common nebulization protocol modifications were characterized, evaluated, and put in perspective using the concept of the dose of aerosolized bronchoconstrictor delivered at the subject airway opening. In agreement with our working hypothesis, it has been shown that nebulization protocol variations can lead to differences in the efficiency of the aerosol delivery at the subject site, in the calculated delivered dose, and in reactivity and sensitivity to aerosolized methacholine in mice. Taken together, these results support the view that protocol modifications as subtle as nebulizer or ventilator setting changes can have a significant impact on respiratory mechanics outcomes and, therefore, should be taken into consideration. Table 1 for details) were plotted against the concentration of methacholine loaded in the nebulizer (A and C), as well as against the average estimated delivered dose for each pattern (B and D). Values are means Ϯ SE; n ϭ 4 -8 animals per group.
Others have applied dose calculation principles similar to those proposed in the present study to report inhaled drug doses in conscious mice (11) or to administer a defined amount of aerosolized methacholine to anesthetized, intubated, spontaneously breathing mice via a feedback dose control system (12, 15) . The dose estimate we derived differs in a few ways from these previous reports. First, it provides an individual estimate of the dose of aerosol received by an anesthetized and mechanically ventilated subject following a challenge, and it is not associated with a feedback control system to deliver a preset amount of an aerosolized agent. Calculation of the delivered dose estimate is based on nebulizer-, ventilator-, and subjectspecific characteristics acquired during prior calibration maneuvers or during the nebulization period itself. This means that there are no firm constraints on the protocol design and that, as a consequence, both the nebulization time and the volume of aerosol produced per unit of time remain constant across increasing aerosolized challenges and between subjects of a given study. We believe that this latter point constitutes an important difference, since our results show an inverse relationship between the nebulizer setting influencing the aerosol density in the inspiratory air, a parameter sometimes used in feedback control loops (15) , and the fraction of aerosol reaching the subject site. As reported in the present study, as well as in a previous study (24) , the loss due to particle impaction and rainout can represent a significant portion of the nebulized aerosol and can also vary according to the details of the nebulization protocol. The fact that it is taken into consideration in the proposed calculations, in addition to other corrections, such as gas compression and transport delays, represents an important element for accurate estimation of the aerosolized dose delivered at a subject's airways. It would be worth mentioning at this point that the fraction of aerosol reaching the subject site did not differ between versions of the flexiVent system (legacy vs. flexiVent FX) for the two nebulizer types tested in the present study under default nebulization settings. This result indicates that both versions of the device should be expected to deliver similar doses at the subject site, at least when the device is operated under the default nebulization pattern built into the operating software (pattern 1). The proportion of the delivered dose that would be deposited within the lungs is not accounted for in the present dose estimation. To be complete and accurate, the determination of that proportion should be considered for each nebulization pattern, mouse strain, and model of respiratory disease of interest, since it is likely to be influenced by the architecture of the airways and the lung, the disease state, and the experimental conditions. Changes in reactivity in response to nebulization protocol variations were consistent with delivered dose changes relative to pattern 1 or with protocol variations previously associated with a deeper penetration of aerosol particles into the lungs (6, 8) , namely, the use of a nebulizer that produces small particles or the addition of a slow deep ventilation profile during nebulizer activation. The latter modification is also associated with significant improvements in sensitivity across airway and peripheral lung mechanics parameters. Its most noticeable effect, however, was on H. An interesting and thus far never reported observation that arose from this work is the identification of a statistically lower sensitivity in H relative to R N or G across nebulization patterns. As these results were obtained using an integrated functional approach in naïve mice, additional research would be needed to expand and further validate them. It is unknown whether similar regional differences in sensitivity exist in other mouse strains or whether they are exaggerated or attenuated in certain models of respiratory diseases. Although the underlying mechanism behind this difference in sensitivity has yet to be clarified, one possible explanation could be that it is related to the amount of drug accessing the peripheral lung.
Of the variant patterns of nebulization studied, the switch from a regular to a slow deep ventilation profile during nebulizer activation (pattern 10) was identified as the modification producing by far the largest overall enhancing effect on airway responsiveness end points relative to the initial protocol (pattern 1). This effect, which was not associated with an increase in the estimated delivered dose, most likely resulted from a more effective aerosol distribution due to deeper lung inflations imposed during the nebulization period. From the other protocol variations that were associated with either improvements of smaller magnitude or worsening effects relative to pattern 1, pattern 13 distinguished itself by its preferential enhancing effect on R N over G or H, suggesting that directed deliveries of aerosolized substances can be performed when nebulizer and ventilator settings are adequately controlled. Pattern 13, which was initially created to minimize the negative effects of visible droplet deposition on subject ventilation and data collection, presents features that could, in certain circumstances, represent study design advantages, namely, a tripling in the fraction of nebulized aerosol reaching the subject site relative to pattern 1 (Table 2) , a very concise drug delivery period (2.5 s), or a preferential airway effect.
The present study was conducted in naïve, spontaneously hyperresponsive A/J mice to circumvent any added variance introduced by a lung disease model. Therefore, the results provide only limited examples of the type of information that can be obtained by incorporating the proposed delivered dose estimate into a study. Airway responsiveness to aerosolized methacholine has been previously reported in A/J mice (1, 3, 5, 7, 20, 21, 23, 25, 34) . However, as explained earlier, because of the lack of standardization mechanisms to account for protocol variations, comparisons between study results are difficult, if not impossible. Comparison of measurements at baseline was, however, possible, and values obtained in the present study are consistent with those reported in the literature (data not shown) (5, 7, 9, 23, 25, 34) .
In a typical AHR study involving control and hyperresponsive subjects, calculation of the delivered dose following increasing aerosolized challenges would be expected, according to Eq. 1, to generate a dose disparity between experimental groups, especially as the hyperresponsive group becomes more bronchoconstricted at the time of nebulization, and present a reduced airflow at the subject's airway opening compared with the control group. This means that each subject is likely to have its own dose-response curve with, as mentioned earlier, possible dose differences between experimental groups. This dose disparity, which always existed and can now be accounted for, is expected to be greater in protocols in which deep lung inflation maneuvers between challenges are omitted because of the nonrestoration of airway patency at the time of nebulization and, therefore, a higher level of bronchoconstriction with increasing number of challenges. Given that the dose delivered at the subject's airways is influenced by the nebulization protocol as well as the subject's respiratory mechanics, access to an individual estimate of the dose of aerosol received by each subject becomes an invaluable tool, not only to refine the AHR assessment procedure, but also to account for and study group-specific effects. While the individualized nature of the approach is likely to challenge the conventional way of presenting and analyzing results, it may also contribute to further emphasize group-specific effects or, as highlighted in the present study, augment the use of individual dose-response curve components, such as the slope, which was recently regarded as clinically relevant and of translational value (36) . A wider use of this approach would also greatly facilitate direct comparison of results between studies or laboratories and contribute to the generation of reproducible research.
In conclusion, the present study demonstrated that nebulization protocol variations during AHR assessment can have a significant impact on the efficiency of the aerosol generation process, the dose delivered, and respiratory mechanics outcomes in naïve mice. The introduction of a delivered dose estimate to account for study-or laboratory-related protocol variations represents an important element to refine, enhance, and standardize the widely performed technique of AHR assessment without imposition of strict study design restrictions or guidelines. The full implication of this work has yet to be demonstrated in studies involving respiratory disease models or their underlying mechanisms.
